Kotyla P - Search Results

1

Etanercept increases adiponectin level in woman with rheumatoid arthritis.

Lewicki M, Kotyla P, Kucharz E. Lewicki M, et al. Among authors: kotyla p. Clin Rheumatol. 2008 Oct;27(10):1337-8. doi: 10.1007/s10067-008-0957-2. Epub 2008 Jul 24. Clin Rheumatol. 2008. PMID: 18651101 No abstract available.

2

Serum level of sFas in patients with Wegener's granulomatosis.

Kucharz EJ, Kotulska AT, Kotyla PJ, Kopeć MM, Krupnik B, Pieczyrak R. Kucharz EJ, et al. Clin Rheumatol. 2006 Feb;25(1):117-8. doi: 10.1007/s10067-005-1160-3. Epub 2005 Jul 15. Clin Rheumatol. 2006. PMID: 16021528 No abstract available.

3

Who might be predisposed to the development of serious side effects when treated with TNF-alpha antagonist?

Kotyla PJ, Kucharz EJ. Kotyla PJ, et al. Clin Exp Rheumatol. 2006 Mar-Apr;24(2):211; author reply 211. Clin Exp Rheumatol. 2006. PMID: 16762164 No abstract available.

4

Treatment with infliximab may contribute to the development of peripheral neuropathy among the patients with rheumatoid arthritis.

Kotyla PJ, Sliwinska-Kotyla B, Kucharz EJ. Kotyla PJ, et al. Clin Rheumatol. 2007 Sep;26(9):1595-6. doi: 10.1007/s10067-007-0657-3. Epub 2007 Jun 5. Clin Rheumatol. 2007. PMID: 17549580 No abstract available.

5

Increased adiponectin levels in women with rheumatoid arthritis after etanercept treatment.

Lewicki M, Kotyla P, Kucharz E. Lewicki M, et al. Among authors: kotyla p. J Rheumatol. 2009 Jun;36(6):1346-7; author reply 1347. doi: 10.3899/jrheum.081192. J Rheumatol. 2009. PMID: 19509093 No abstract available.

6

Infliximab treatment increases left ventricular ejection fraction in patients with rheumatoid arthritis: assessment of heart function by echocardiography, endothelin 1, interleukin 6, and NT-pro brain natriuretic peptide.

Kotyla PJ, Owczarek A, Rakoczy J, Lewicki M, Kucharz EJ, Emery P. Kotyla PJ, et al. J Rheumatol. 2012 Apr;39(4):701-6. doi: 10.3899/jrheum.110751. Epub 2012 Feb 15. J Rheumatol. 2012. PMID: 22337242 Clinical Trial.

7

Etanercept increases tumor necrosis factor-alpha level but not sFas level in patients with rheumatoid arthritis.

Kotyla P, Jankiewicz-Ziobro K, Owczarek A, Kucharz EJ. Kotyla P, et al. Isr Med Assoc J. 2015 Jan;17(1):14-8. Isr Med Assoc J. 2015. PMID: 25739170 Clinical Trial.

8

Plasma Glycosaminoglycan Profiles in Systemic Sclerosis: Associations with MMP-3, MMP-10, TIMP-1, TIMP-2, and TGF-Beta.

Kuźnik-Trocha K, Winsz-Szczotka K, Komosińska-Vassev K, Jura-Półtorak A, Kotulska-Kucharz A, Kucharz EJ, Kotyla P, Olczyk K. Kuźnik-Trocha K, et al. Among authors: kotyla p. Biomed Res Int. 2020 Apr 21;2020:6416514. doi: 10.1155/2020/6416514. eCollection 2020. Biomed Res Int. 2020. PMID: 32382564 Free PMC article. Clinical Trial.

9

Pravastatin, a 3-hydroxy-3-methyl-glutharyl coenzyme A inhibitor does not show pleiotropic effects in patients with systemic lupus erythematosus.

Kotyla PJ. Kotyla PJ. Rheumatol Int. 2009 Jan;29(3):353-4. doi: 10.1007/s00296-008-0683-8. Epub 2008 Aug 23. Rheumatol Int. 2009. PMID: 18726102 No abstract available.

10

Insulin resistance varies across connective tissue diseases patients: comparison between rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis.

Kotyla PJ. Kotyla PJ. Clin Exp Rheumatol. 2019 Nov-Dec;37 Suppl 122(6):14. Epub 2019 Jan 10. Clin Exp Rheumatol. 2019. PMID: 30652676 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results